Mark Trifiro

Mark Trifiro

Auto-generated profile, based on publicly available information

Mark Trifiro

Lady Davis Institute for Medical Research - Jewish General Hospital

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
SMShauna R. McGee
Shauna R. McGee
CTChabane Tibiche
Chabane Tibiche
MTMark Trifiro
Mark Trifiro
EWEdwin Wang
Edwin Wang
Mutated genes are rarely common even in the same pathological type between cancer patients and as such, it has been very challenging to interpret genome sequencing data and difficult to predict clinical outcomes. PIK3CA is one of a few genes whose mutations are relatively popular in tumors. For example, more than 46.6% of luminal-A breast cancer samples have PIK3CA mutated, whereas only 35.5% of all breast cancer samples contain PIK3CA mutations. To understand the function of PIK3CA mutations in luminal A breast cancer, we applied our recently-proposed Cancer Hallmark Network Framework to investigate the network motifs in the PIK3CA-mutated luminal A tumors. We found that more than 70% of the PIK3CA-mutated luminal A tumors contain a positive regulatory loop where a master regulator (PDGF-D), a second regulator (FLT1) and an output node (SHC1) work together. Importantly, we found the luminal A breast cancer patients harboring the PIK3CA mutation and this positive regulatory loop in their tumors have significantly longer survival than those harboring PIK3CA mutation only in their tumors. These findings suggest that the underlying molecular mechanism of PIK3CA mutations in luminal A patients can participate in a positive regulatory loop, and furthermore the positive regulatory loop (PDGF-D/FLT1/SHC1) has a predictive power for the survival of the PIK3CA-mutated luminal A patients.

1 October 1999 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
ZYZhi Qiang Yuan
Zhi Qiang Yuan
NWNora Wong
Nora Wong
WFWilliam Foulkes
William Foulkes
LALesley Alpert
Lesley Alpert
FMFortunato Manganaro
Fortunato Manganaro
DLDana Lasko
Dana Lasko

30 November 2023 in Biomedical Optics Express
Verified
Journal Article
Open access
FOFatma Oudjedi
Fatma Oudjedi
SLSeung Soo Lee
Seung Soo Lee
MPMiltiadis Paliouras
Miltiadis Paliouras
MTMark Trifiro
Mark Trifiro
AKAndrew G Kirk
Andrew G Kirk
Photothermal therapy (PTT) is a promising approach for cancer treatment that selectively heats malignant cells while sparing healthy cells. Here, the light-to-heat conversion efficiency of multiwalled carbon nanotubes (MWCNTs) within the near-infrared biological transmission window is enhanced by decorating them with plasmonic gold nanorods (GNRs). The results reveal a significant photothermal enhancement of hybrid MWCNTs-GNRs compared to bare MWCNTs, displaying a 4.9 enhancement factor per unit mass. The enhanced plasmonic PTT properties of MWCNTs-GNRs are also investigated in vitro using PC3 prostate cancer cell lines, demonstrating a potent ablation efficiency. These findings advance innovative hybrid plasmonic nanostructures for clinical applications.

27 May 2004 in Human Mutation
Verified
Journal Article
Open access
PDF file
BGBruce Gottlieb
Bruce Gottlieb
LBLenore K. Beitel
Lenore K. Beitel
JWJian Hui Wu
Jian Hui Wu
MTMark Trifiro
Mark Trifiro
The original article to which this Erratum refers was published in Human Mutation 23:527–533Human Mutation(2004) 23(6) 527–533